JC Discovery

JC Discovery is a science-driven partner offering a unique combination of know-how from its founding company CIPHE (Center of ImmunoPHEnomics), located in France. With a unique platform and BSL3 laboratory, JC Discovery helps pharma and biotech companies validate their drug candidates with efficient and innovative solutions, early. With decades of experience leading successful translational projects of new mouse model creation and humanization together with high content immunoprofiling, JC Discovery offers strategic custom services to elucidate the mechanisms of action and interactions; identify, validate and prioritize new therapeutic targets in the field of immuno-oncology, inflammatory, autoimmune and infectious diseases. Using a multiomics state-of-the-art technology platform, JC Discovery has also developed innovative approaches of primary T cells editing aiming to optimize drug candidates at an early stage of development with 3Rs in vitro and in vivo dedicated services.

Site web

www.jc-discovery.com

Lien externe pour JC Discovery

Secteur

Recherche en biotechnologie

Taille de l’entreprise

2-10 employés

Siège social

Marseille

Type

Société civile/Société commerciale/Autres types de sociétés

Fondée en

2022

Domaines

Drug profiling, Drug target validation, Drug mechanism of action, High content flow cytometry, Challenge testing, Humanized models, Knock-in mice, Knock-out mice, BSL3, CIPHE, Immunophenomics, Tumor microenvironnement, BSL3, Immuno-oncology, Translational research, Predictive models, Lead candidate, Drug discovery, Drug development, CAR-T cells, CAR-NK cells, Bispecific antibodies, Fast-Track design, Fast-Track Immunomics, Fast-Track Breeding, Fast-Track Delivery, Functional GEM, Functional HU-GEM et Humanized mouse models